Top Markets
Coin of the day
CARGO Therapeutics, Inc. Common Stock CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock

CRGX
Rangering i aksjer #18091
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company... CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Aksjekurs
$4.47
Sist synkronisert: 2025-08-20
Markedsverdi
$213.06M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel CARGO Therapeutics, Inc. Common Stock (CRGX)

Kategori

Inntekter for CARGO Therapeutics, Inc. Common Stock (CRGX)
Inntekter i Sep 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til CARGO Therapeutics, Inc. Common Stock er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for CARGO Therapeutics, Inc. Common Stock fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH